ReviewBlood cancer journal2024
Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors.
Review in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Thrombotic burden and longitudinal outcomes in Thai patients with polycythemia vera.Annals of medicine · 2026Article
- Microbiota-Inflammation Crosstalk in Myeloproliferative Neoplasms: MPN-Specific Human Data, Mechanistic Plausibility and Translational Priorities.Biomedicines · 2026Review
- Molecular Abnormalities and Associated Clinical Features in Polycythemia Vera.Medical sciences (Basel, Switzerland) · 2026Review
- Preserving thrombosis and life years in polycythemia vera: start by reading the biology of the disease.Haematologica · 2026Article
- Clinical Impact of Next-Generation Sequencing-Detected Mutations on Thrombotic Events in Myeloproliferative Neoplasms.International journal of laboratory hematology · 2026Article
- Arterial thrombosis and cancer: insights from observations in myeloproliferative neoplasms and CHIP.Blood cancer journal · 2026Article
- Polycythemia Vera, Thrombophilia, CTEPH, Cerebral Venous Sinus Thrombosis and Vertebral Artery Occlusion: A Case-Illustrated Narrative Review of Competing Thrombotic and Hemorrhagic Risks.Life (Basel, Switzerland) · 2026Article
- Beyond the JAK2 mutation: The inflammasome, clonal stability, and the thrombotic niche in myeloproliferative neoplasms.Clinical and experimental medicine · 2026Review
- Positive and Negative Cardiovascular Effects of JAK Inhibitors in Inflammation.ACR open rheumatology · 2026Review
- Prognostic Scores and Risk Stratification of Myeloproliferative Neoplasms: 2026 Updates.Cancers · 2026Review
- Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera.Blood cancer journal · 2026Article
- Carotid Pseudoaneurysm Repair in a Patient with Myeloproliferative Disorder Complicated by Contralateral Stroke, Graft Thrombosis, Pyoderma Gangrenosum, and Superinfection: A Case Report.Journal of clinical medicine · 2026Article
- Review
- Review
- 4G/5G polymorphism and plasma levels of plasminogen activator inhibitor-1 in essential thrombocythemia patients with driver mutational status.Thrombosis journal · 2026Article
- Critical Appraisal of Limitations in the Study on JAK2V617F Zygosity and Disease Outcomes in MPNs.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Clinical and Molecular Insights of Arterial and Venous Thrombosis in Myeloproliferative Diseases-Case-Based Narrative Review.Biomedicines · 2025Review
- Consequences and impacts of PEG-IFNα2a shortage: first lessons from a MPN French center.Annals of hematology · 2025Article
- Molecular predictors of venous and arterial thrombotic events in patients with myelofibrosis.Annals of hematology · 2025Article
- Risk factors for thrombotic events in Philadelphia chromosome-negative myeloproliferative neoplasms: a retrospective analysis of 336 cases.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This viewpoint summarizes findings from analyses of large personal patient databases of myeloproliferative neoplasms (MPNs) to assess the impact of thrombosis on mortality, disease progression, and second cancers (SC). Despite advances, the current incidence of arterial and venous thrombosis remains a challenge. These events appear to signal a more aggressive disease course, as evidenced by their association with myelofibrosis progression and mortality using multistate models and time-dependent multivariable analysis. Inflammatory biomarkers, such as the neutrophil-to-lymphocyte ratio (NLR), are associated with the aggressiveness of polycythemia vera (PV) and essential thrombocythemia (ET), linking thrombosis to SC risk. This suggests a common inflammatory pathway likely influencing cardiovascular disease and cancer incidence. Notably, this is observed more frequently in younger patients, likely due to prolonged exposure to MPN and environmental inflammatory triggers. These data underscore the need for new studies to validate these associations, delineate the sequence of events, and identify therapeutic targets to mitigate thrombotic events and potentially improve overall patient outcomes in MPN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.